Anaplastic Astrocytoma - Pipeline Review, H1 2020
Anaplastic Astrocytoma - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma – Pipeline Review, H1 2020, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.
Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma – Pipeline Review, H1 2020, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 10, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.
Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Anaplastic Astrocytoma - Overview
Anaplastic Astrocytoma - Therapeutics Development
Anaplastic Astrocytoma - Therapeutics Assessment
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
Anaplastic Astrocytoma - Drug Profiles
Anaplastic Astrocytoma - Dormant Projects
Anaplastic Astrocytoma - Discontinued Products
Anaplastic Astrocytoma - Product Development Milestones
Appendix
Anaplastic Astrocytoma - Overview
Anaplastic Astrocytoma - Therapeutics Development
Anaplastic Astrocytoma - Therapeutics Assessment
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
Anaplastic Astrocytoma - Drug Profiles
Anaplastic Astrocytoma - Dormant Projects
Anaplastic Astrocytoma - Discontinued Products
Anaplastic Astrocytoma - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Anaplastic Astrocytoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Anaplastic Astrocytoma - Pipeline by AbbVie Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Aduro BioTech Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Aettis Inc, H1 2020
Anaplastic Astrocytoma - Dormant Projects, H1 2020
Anaplastic Astrocytoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anaplastic Astrocytoma - Discontinued Products, H1 2020
Number of Products under Development for Anaplastic Astrocytoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Anaplastic Astrocytoma - Pipeline by AbbVie Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Aduro BioTech Inc, H1 2020
Anaplastic Astrocytoma - Pipeline by Aettis Inc, H1 2020
Anaplastic Astrocytoma - Dormant Projects, H1 2020
Anaplastic Astrocytoma - Dormant Projects, H1 2020 (Contd..1), H1 2020
Anaplastic Astrocytoma - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Anaplastic Astrocytoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Adastra Pharmaceuticals Inc
Aduro BioTech Inc
Aettis Inc
AngioChem Inc
Apexigen Inc
Astellas Pharma Inc
Bayer AG
Berg LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Candel Therapeutics
CDG Therapeutics Inc
Deciphera Pharmaceuticals Inc
Everfront Biotech Inc
Ipsen SA
Kazia Therapeutics Ltd
Mustang Bio Inc
Novartis AG
Orbus Therapeutics Inc
Pfizer Inc
PTC Therapeutics Inc
Taiho Oncology Inc
TheraBiologics Inc
Vanquish Oncology Inc
Wayshine Biopharma Inc
ZIOPHARM Oncology Inc
Number of Products under Development for Anaplastic Astrocytoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
AbbVie Inc
Adastra Pharmaceuticals Inc
Aduro BioTech Inc
Aettis Inc
AngioChem Inc
Apexigen Inc
Astellas Pharma Inc
Bayer AG
Berg LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Candel Therapeutics
CDG Therapeutics Inc
Deciphera Pharmaceuticals Inc
Everfront Biotech Inc
Ipsen SA
Kazia Therapeutics Ltd
Mustang Bio Inc
Novartis AG
Orbus Therapeutics Inc
Pfizer Inc
PTC Therapeutics Inc
Taiho Oncology Inc
TheraBiologics Inc
Vanquish Oncology Inc
Wayshine Biopharma Inc
ZIOPHARM Oncology Inc
